<DOC>
	<DOCNO>NCT00464737</DOCNO>
	<brief_summary>This trial investigate efficacy safety rotigotine compare placebo reduce sign symptom fibromyalgia syndrome . The effect rotigotine pain , sleep , general activity , mood , quality life , use rescue medication treat pain assess .</brief_summary>
	<brief_title>The Use Rotigotine Treatment Reducing Signs Symptoms Fibromyalgia Adults .</brief_title>
	<detailed_description>The overall post-Baseline duration treatment 13 week . The trial consist 4-week Titration Phase , 8-week Maintenance Phase , 1-week De-escalation Phase , 2-week Safety Follow-Up Phase . If subject meet eligibility criterion , randomize receive rotigotine 4 mg/24 hr , rotigotine 8 mg/24 hr , placebo Maintenance Phase . During 4-week Titration Phase , subject assign rotigotine titrate weekly interval 2 mg/24 hrs reach 4 mg/24 hr 8 mg/24 hr . All subject complete 4-week Titration Phase enter 8-week Maintenance Phase maintain randomize dose ( rotigotine 4 mg/24 hr , rotigotine 8 mg/24 hr , placebo ) . No dose adjustment allow Maintenance Phase . The Treatment Phase define combined Titration Maintenance Phases .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject male female , 18 65 year age ( inclusive ) Subject fulfill 3 point American College Rheumatology ( ACR ) definition diagnosis fibromyalgia ( pain , stiffness , and/or sleep disorder ) Subject must complete adequate washout period exclude medication , necessary , prior begin Baseline Diary Phase Subject least moderate pain define average pain intensity ≥5 11point Likert pain scale ( 010 ) 7 day prior Baseline Subject must least 5 morning 5 evening Likert pain scale score 7 day immediately prior Visit 2 average daily pain score 7 day must ≥5 ( average daily pain score determined follow : calculate mean morning evening score separately use pain score 7 day immediately prior Visit 2 ; add mean morning evening score divide 2 ) Subject score ≥50 Fibromyalgia Impact Questionnaire ( FIQ ) , score 100 represent severe disease Baseline Subject symptomatic regional structural rheumatic disease ( eg , knee hip osteoarthritis , bursitis , tendonitis ) , rheumatic autoimmune disease inflammatory rheumatic disease , systemic lupus erythematosus ( SLE ) , mild primary osteoarthritis hand ( ) allow Subject diagnose neuropathic pain syndrome Subject receive therapy dopamine agonist ( eg , pramipexole , ropinirole ) 3 month longer consider effective manage fibromyalgia symptom Subject receive disability involve litigation relate fibromyalgia syndrome Subject significant psychopathology determine investigator base result Structural Clinical Interview DSMIV Diagnosis ( SCIDI ) . The SCIDI must administer physician clinical psychologist train administer instrument Subject evidence impulse control disorder accord Jay Modified Minnesota Impulsive Disorders Interview ( MIDI ) Subject medical condition , opinion investigator , could jeopardize compromise subject 's ability participate trial Subject orthostatic hypotension decrease blood pressure ( BP ) supine stand position ≥20 mmHg systolic blood pressure ( SBP ) ≥10 mmHg diastolic blood pressure ( DBP ) take 5minute supine value 1 and/or 3minute standing measurement , supine SBP &lt; 105 mmHg Baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Fibromyalgia Syndrome</keyword>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
</DOC>